Cell-surface reactivity of post-alloHSCT serum antibodies
| . | Autologous B-CLL cells . | Autologous T cells . | Allogeneic B cells . | Third-party B cells . |
|---|---|---|---|---|
| Patient A after 6 m plasma | ++* | + | −† | Weak |
| Patient B after 10 m plasma | ++ | Weak | ++‡ | + |
| Rituximab | ++ (Patient A) | − (Patient A) | ++ | ++ |
| + (Patient B) | − (Patient B) | ++ | ++ | |
| Alemtuzumab | +++ (Patient A) | − (Patient A) | +++ | +++ |
| +++ (Patient B) | − (Patient B) | +++ | +++ |
| . | Autologous B-CLL cells . | Autologous T cells . | Allogeneic B cells . | Third-party B cells . |
|---|---|---|---|---|
| Patient A after 6 m plasma | ++* | + | −† | Weak |
| Patient B after 10 m plasma | ++ | Weak | ++‡ | + |
| Rituximab | ++ (Patient A) | − (Patient A) | ++ | ++ |
| + (Patient B) | − (Patient B) | ++ | ++ | |
| Alemtuzumab | +++ (Patient A) | − (Patient A) | +++ | +++ |
| +++ (Patient B) | − (Patient B) | +++ | +++ |
− indicates < 2; weak, ≥ 2 and < 5; +, ≥ 5 and < 20; ++, ≥ 20 and < 100; and +++, ≥ 100
Based on median fluorescence intensity (MFI) ratios calculated for sample over background.
Allogeneic B cells derived from PBMCs of patient A 15 months after transplantation.
Allogeneic B cells derived from PBMCs of the donor of patient B.